
Caris Life Sciences Posts Surprise Profit as Cancer Detection Test Shows Clinical Superiority
Caris Life Sciences beat earnings expectations with 28-cent EPS and 125% revenue growth. Its cancer detection test showed clinical superiority, driving 20% stock gains.
CAIcancer detectionearly detection test